---
title: Viking Therapeutics (VKTX) — Wall Street analysts' targets, grades and estimates
canonical: https://sweetvaluelab.com/stocks/vktx/analysts
ticker: VKTX
as_of: 2026-11-02
sector: Healthcare
---
# Viking Therapeutics (VKTX) — Wall Street analysts

3 firms published a price target for VKTX in the last 90 days. Counting each firm once, at its latest, the median target is $85.00, 212% above the last close of $27.28 (Oct 30, 2026); the lowest is $34.00 and the highest $120.00.

These are the analysts' figures, quoted, not this site's. The site's own model value for VKTX is on the valuation page: https://sweetvaluelab.com/stocks/vktx/valuation.

## At a glance

| Figure | Value |
| --- | ---: |
| Median target (each firm's latest, last 90 days) | $85.00 |
| Median target vs last close | +212% |
| Firms with a target, last 90 days | 3 |
| Lowest – highest target | $34.00 – $120.00 |
| Current grades of 6 firms: positive / neutral / negative | 6 / 0 / 0 |
| Upgrades / downgrades, last 12 months | 0 / 0 |

## Each firm's latest target (last 90 days)

Newest first. Change is against the same firm's previous target; the last two columns are the target against the close on the day it was published and against the last close.

| Date | Firm | Target | Previous | Change | Vs price then | Vs price now | Report |
| --- | --- | ---: | ---: | ---: | ---: | ---: | --- |
| 2026-10-29 | Goldman Sachs | $34.00 | — | — | +34% | +25% | https://thefly.com/ajax/news_get.php?id=4452444 |
| 2026-10-07 | Truist | $85.00 | $87.00 | −2% | +195% | +212% | https://thefly.com/ajax/news_get.php?id=4437371 |
| 2026-09-22 | Oppenheimer | $120.00 | $100.00 | +20% | +211% | +340% | https://thefly.com/ajax/news_get.php?id=4429269 |

## Current grades (each firm's latest, last 12 months)

| As of | Firm | Grade |
| --- | --- | --- |
| 2026-10-30 | Canaccord Genuity | “Buy” |
| 2026-10-07 | Truist | “Buy” |
| 2026-08-11 | J.P. Morgan | “Overweight” |
| 2026-05-01 | BTIG | “Buy” |
| 2026-04-30 | Cantor Fitzgerald | “Overweight” |
| 2026-03-23 | H.C. Wainwright | “Buy” |

## Grade changes (last 24 months)

None in the last 24 months.

4 older changes are listed on the page.

## Consensus estimates by fiscal year

A reported year shows the company's revenue and GAAP diluted EPS with the consensus beside it; a later year shows the consensus average and its range. The analysts' EPS usually leaves items such as stock compensation out, so reported and estimated EPS are not like for like.

| Fiscal year | Status | Revenue | YoY | EPS | YoY | Consensus revenue | Consensus EPS | Analysts |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| 2020 | reported | $0 | — | -$0.50 | — | $6.2M (reported −100% vs it) | -$0.55 | 18 |
| 2025 | reported | $0 | — | -$3.19 | — | $1.5M (reported −100% vs it) | -$2.72 | 11 |
| 2026 | estimate | $7.2M | — | -$5.32 | — | $7.2M – $7.2M | -$6.38 – -$4.54 | 9 |
| 2027 | estimate | $7.3M | +3% | -$5.15 | — | $7.3M – $7.3M | -$7.62 – -$2.81 | 10 |
| 2028 | estimate | $217.2M | +2855% | -$3.93 | — | $207.6M – $226.7M | -$6.62 – $1.22 | 15 |
| 2029 | estimate | $482.5M | +122% | -$1.69 | — | $482.5M – $482.5M | -$1.69 – -$1.69 | 10 |
| 2030 | estimate | $1.1B | +138% | $1.66 | — | $1.1B – $1.1B | $1.66 – $1.66 | 7 |

---

Source: https://sweetvaluelab.com/stocks/vktx/analysts (SweetValueLab, free, no account). Targets, grades and estimates are the analysts' own, quoted from Financial Modeling Prep's analyst feeds; reported figures from the company's statements. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.